Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
80Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.18B | $-116.38M | $-0.61 |
Social Signal Score
Earnings
Fri, Nov 6(in 3 months)
Consensus estimate $0.09 per share
Typical surprise -65.5% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-2.11 vs $0.06miss
- Thu, May 7$0.01 vs $-0.01beat
- Thu, Feb 26$-0.22 vs $-0.07miss
- Wed, Nov 5$-0.14 vs $-0.08miss
- Wed, Aug 6$-0.07 vs $-0.06miss
- Wed, May 7$-0.17 vs $-0.07miss
Estimates and results for TRLV via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
TRLVhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (1)
- Newsprnewswire.com·3d ago·Negative
Trulieve Completes Redomicile from British Columbia to Delaware TALLAHASSEE, Fla., Aug. 11, 2026 /PRNewswire/ -- Trulieve Cannabis Corp. (NYSE: TRLV) ("Trulieve" or "the Company"), a leading and top-performing medical cannabis company in the U.S., today announced the completion of its previously announced plan to redomicile Trulieve Cannabis Corp. from British Columbia, Canada to Delaware, United States.
View source ↗
